Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Clolar Approved For Pediatric Acute Lymphoblastic Leukemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Indication follows advisory committee recommendation to approve clofarabine for ALL but not for pediatric acute myelogenous leukemia. Genzyme will have to redesign its confirmatory trial within two months.
Advertisement

Related Content

Genzyme Clolar Confirmatory Pediatric Study Should Enroll Early Relapse Leukemia Patients, Cmte. Says
Genzyme Clolar Confirmatory Pediatric Study Should Enroll Early Relapse Leukemia Patients, Cmte. Says
Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient
Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML

Topics

Advertisement
UsernamePublicRestriction

Register

PS058477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel